Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts
Zhouling Xie, Shuzeng Hou, Xiaoxiao Yang, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 9, pp. 6356-6389
Closed Access | Times Cited: 45

Showing 26-50 of 45 citing articles:

Advances in the Delivery and Development of Epigenetic Therapeutics for the Treatment of Cancer
Aparajita Ghosh, Ambati Himaja, Swati Biswas, et al.
Molecular Pharmaceutics (2023) Vol. 20, Iss. 12, pp. 5981-6009
Closed Access | Times Cited: 3
CDK6 is a novel predictive and prognosis biomarker correlated with immune infiltrates in multiple human neoplasms, including small cell lung carcinoma
Guosheng Li, Zhi-Guang Huang, Dongming Li, et al.
Functional & Integrative Genomics (2023) Vol. 23, Iss. 4
Closed Access | Times Cited: 3
Focusing on cyclin-dependent kinases 5: A potential target for neurological disorders
Zhen Tian, Bin Feng, Xing-Qin Wang, et al.
Frontiers in Molecular Neuroscience (2022) Vol. 15
Open Access | Times Cited: 6
Design, synthesis and biological evaluation of pteridine-7(8H)-one derivatives as potent and selective CDK4/6 inhibitors
Huan He, Qi Liu, Lü Chen, et al.
Bioorganic & Medicinal Chemistry Letters (2022) Vol. 76, pp. 128991-128991
Closed Access | Times Cited: 5
Selective mono-N-methylation of amines using methanol as a methylating reagent over heterogeneous Ni catalysts
Pan Wang, Ziliang Yuan, Chensheng Xian, et al.
Catalysis Science & Technology (2022) Vol. 13, Iss. 2, pp. 315-320
Closed Access | Times Cited: 5
An Interpretable Multitask Framework BiLAT Enables Accurate Prediction of Cyclin-Dependent Protein Kinase Inhibitors
Qian Xu, Xiaowen Dai, Lin Luo, et al.
Journal of Chemical Information and Modeling (2023) Vol. 63, Iss. 11, pp. 3350-3368
Closed Access | Times Cited: 2
Discovery of SHR5428 as a selective and noncovalent inhibitor of CDK7
Minqiang Jia, Weimin Wang, Gang Chen, et al.
Bioorganic & Medicinal Chemistry Letters (2023) Vol. 93, pp. 129429-129429
Closed Access | Times Cited: 2
Discovery of Selective Tertiary Amide Inhibitors of Cyclin-Dependent Kinase 2 (CDK2)
Mingshuo Zeng, Jessica M. Grandner, Marian C. Bryan, et al.
ACS Medicinal Chemistry Letters (2023) Vol. 14, Iss. 9, pp. 1179-1187
Open Access | Times Cited: 2
Discovery of the Novel 1H-Pyrrolo[2,3-b]pyridine Derivative as a Potent Type II CDK8 Inhibitor against Colorectal Cancer
Xing Xing Zhang, Yun Xiao, Yao Yao Yan, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 18, pp. 12095-12123
Closed Access | Times Cited: 4
Selective Cyclin-Dependent Kinase Inhibitors and Their Application in Cancer Therapy
Robert B. Kargbo
ACS Medicinal Chemistry Letters (2022) Vol. 13, Iss. 10, pp. 1561-1563
Open Access | Times Cited: 4
Bruceantinol works as a CDK2/4/6 inhibitor to inhibit the growth of breast cancer cells
Li Sun, Yumeng Wang, Jia Li, et al.
Chemico-Biological Interactions (2024) Vol. 395, pp. 110999-110999
Open Access
Cancer therapy by cyclin-dependent kinase inhibitors (CDKIs): bench to bedside.
Ali Hassanzadeh, Navid Shomali, Amin Kamrani, et al.
PubMed (2024) Vol. 23, pp. 862-882
Closed Access
Inhibitors and PROTACs of CDK2: challenges and opportunities
Yangjie Zeng, Xiaodong Ren, Pengyao Jin, et al.
Expert Opinion on Drug Discovery (2024) Vol. 19, Iss. 9, pp. 1125-1148
Closed Access
Dual Inhibitors of CDK4 /6 for Treating Cancer
Peter L. Toogood
(2024), pp. 319-337
Closed Access
Synthesis of N-Substituted 3-Hydroxypyridinium Salts from Bioderived 5-Hydroxymethylfurfural in Water
Shasha Zheng, Soumyadeep Chakrabortty, Eszter Baráth, et al.
ACS Sustainable Chemistry & Engineering (2022) Vol. 10, Iss. 48, pp. 15642-15647
Closed Access | Times Cited: 3
Pyrazolo[4,3-H]quinazolines as Cyclin-dependent Kinase Inhibitors for Treating Cancer
Surya K. De
Current Medicinal Chemistry (2023) Vol. 31, Iss. 8, pp. 1040-1043
Closed Access | Times Cited: 1
Discovery of small molecule degraders for modulating cell cycle
Liguo Wang, Zhouli Yang, Guangchen Li, et al.
Frontiers of Medicine (2023) Vol. 17, Iss. 5, pp. 823-854
Closed Access | Times Cited: 1
RECENT ADVANCES IN THE DISCOVERY OF CYCLIN-DEPENDENT KINASE 2 (CDK2) SELECTIVE INHIBITORS
Kevin D. Freeman‐Cook, Robert L. Hoffman
Medicinal chemistry reviews (2023), pp. 283-311
Closed Access
The discovery of high affinity and metabolically stable allosteric cyclin-dependent kinase 2 (CDK2) inhibitors from screening through lead optimization
Erik B. Faber, Nan Wang, Kristen John, et al.
(2022)
Open Access
The discovery of high affinity and metabolically stable allosteric cyclin-dependent kinase 2 (CDK2) inhibitors from screening through lead optimization
Erik B. Faber, Nan Wang, Kristen John, et al.
(2022)
Open Access
Previous Page - Page 2

Scroll to top